DXCM
DexCom Inc
NASDAQ: DXCM · HEALTHCARE · MEDICAL DEVICES
$60.61
-0.49% today
Updated 2026-05-08
Market cap
$23.50B
P/E ratio
26.14
P/S ratio
4.88x
EPS (TTM)
$2.33
Dividend yield
—
52W range
$54 – $90
Volume
4.4M
WallStSmart proprietary scores
72
out of 100
Grade: B
Buy
Investment rating
8.7
Growth
A6.5
Quality
B8.5
Profitability
A7.3
Valuation
B+5/9
Piotroski F-Score
Moderate
2.6
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$83.54
+37.83%
12-Month target
$63.19
+4.26%
Intrinsic (DCF)
$679.65
Margin of safety
+89.97%
4 Strong Buy20 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 35.60% — strong efficiency
+ Free cash flow $449.00M — positive
+ Revenue growth 15.00% QoQ
+ 89.97% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $2.91B | $3.62B | $4.03B | $4.66B | $4.82B | $5.3B |
| Net income | $341.20M | $541.50M | $576.20M | $836.30M | $199.50M | — |
| EPS | — | — | — | — | $2.33 | $2.54 |
| Free cash flow | $304.70M | $511.90M | $630.70M | $1.08B | $449.00M | — |
| Profit margin | 11.73% | 14.95% | 14.29% | 17.94% | 19.30% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | BROWN, MICHAEL JON | Sale | 1,700 | $63.04 |
| 2026-03-16 | BROWN, MICHAEL JON | Sale | 1,700 | $64.85 |
| 2026-03-08 | SYLVAIN, JEREME M | Buy | 48,774 | — |
Peer comparison
Smart narrative
DexCom Inc trades at $60.61. representing a P/E of 26.14x trailing earnings. Our Smart Value Score of 72/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.56, it sits in the grey zone. TTM revenue stands at $4.82B. with profit margins at 19.30%. Our DCF model estimates intrinsic value at $679.65.
Frequently asked questions
What is DexCom Inc's stock price?
DexCom Inc (DXCM) trades at $60.61.
Is DexCom Inc overvalued?
Smart Value Score 72/100 (Grade B, Buy). DCF value $679.65.
What is the price target of DexCom Inc (DXCM)?
The analyst target price is $83.54, representing +37.8% upside from the current price of $60.61.
What is the intrinsic value of DexCom Inc (DXCM)?
Based on our DCF model, intrinsic value is $679.65, a +90.0% margin of safety versus $60.61.
What is the future stock price of DXCM by 2030?
Our research-backed model estimates DexCom Inc could reach $261.32 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is DexCom Inc's revenue?
TTM revenue is $4.82B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
2.56 — grey zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.88x
ROE35.60%
Beta1.40
50D MA$65.06
200D MA$69.13
Shares out0.39B
Float0.38B
Short ratio—
Avg volume4.4M
Performance
1 week-1.21%
1 month-5.33%
3 months-13.38%
YTD-8.68%
1 year—
3 years—
5 years—